Difference between revisions of "Breaking And Entering"
m (→Notes: added note about high crimes and misdemeanors) |
m (→Notes: small formatting fix) |
||
| Line 87: | Line 87: | ||
* Daniel found the [[lemniscate]] symbols again, on the boxes he found at the warehouse. The boxes contained styrofoam, and Epogen. This might be the stuff that was injected into Bree. | * Daniel found the [[lemniscate]] symbols again, on the boxes he found at the warehouse. The boxes contained styrofoam, and Epogen. This might be the stuff that was injected into Bree. | ||
| − | * Breaking and Entering is usually treated as a misdemeanor in the United States. Daniel learned many of his Breaking and Entering skills in the video [[Following The Helper]] in which he broke into [[Lucy]]'s apartment. In this video, Daniel also steals something from the warehouse, which would be treated as burglary. Burglary is typically a felony in the United States. As in the past, Daniel is unconcerned about posting footage of criminal acts on | + | * Breaking and Entering is usually treated as a misdemeanor in the United States. Daniel learned many of his Breaking and Entering skills in the video [[Following The Helper]] in which he broke into [[Lucy]]'s apartment. In this video, Daniel also steals something from the warehouse, which would be treated as burglary. Burglary is typically a felony in the United States. As in the past, Daniel is unconcerned about posting footage of criminal acts on [[YouTube]]. |
* About Epogen: EPOGEN® is indicated for the treatment of anemia in patients with chronic renal failure on dialysis. Important Product Safety Information EPOGEN® is contraindicated in patients with uncontrolled hypertension. Erythropoietic therapies may increase the risk of seizures, thrombotic events, and other serious events. The target hemoglobin (Hb) should not exceed 12 g/dL. If the Hb increase exceeds 1.0 g/dL in any 2-week period, dose reductions are recommended. In a study with hemodialysis patients with clinically evident cardiac disease, where the target hematocrit (Hct) was 42% (Hb = 14 g/dL), an increased incidence of thrombotic events and mortality was seen. The reason for increased mortality observed in this study is unknown.Cases of pure red cell aplasia (PRCA) and of severe anemia, with or without other cytopenias associated with neutralizing antibodies to erythropoietin, have been reported in patients treated with EPOGEN®. A sudden loss of response to EPOGEN®, accompanied by severe anemia and low reticulocyte count, should be evaluated. If anti-erythropoietin antibody-associated anemia is suspected, withhold EPOGEN® and other erythropoietic proteins. EPOGEN® should be permanently discontinued in patients with antibody-mediated anemia. Patients should not be switched to other erythropoietic proteins.The most commonly reported side effects in clinical trials were hypertension, headache, arthralgias, and nausea. | * About Epogen: EPOGEN® is indicated for the treatment of anemia in patients with chronic renal failure on dialysis. Important Product Safety Information EPOGEN® is contraindicated in patients with uncontrolled hypertension. Erythropoietic therapies may increase the risk of seizures, thrombotic events, and other serious events. The target hemoglobin (Hb) should not exceed 12 g/dL. If the Hb increase exceeds 1.0 g/dL in any 2-week period, dose reductions are recommended. In a study with hemodialysis patients with clinically evident cardiac disease, where the target hematocrit (Hct) was 42% (Hb = 14 g/dL), an increased incidence of thrombotic events and mortality was seen. The reason for increased mortality observed in this study is unknown.Cases of pure red cell aplasia (PRCA) and of severe anemia, with or without other cytopenias associated with neutralizing antibodies to erythropoietin, have been reported in patients treated with EPOGEN®. A sudden loss of response to EPOGEN®, accompanied by severe anemia and low reticulocyte count, should be evaluated. If anti-erythropoietin antibody-associated anemia is suspected, withhold EPOGEN® and other erythropoietic proteins. EPOGEN® should be permanently discontinued in patients with antibody-mediated anemia. Patients should not be switched to other erythropoietic proteins.The most commonly reported side effects in clinical trials were hypertension, headache, arthralgias, and nausea. | ||
Revision as of 15:25, 22 December 2006
Breaking and Entering is the one-hundred and third video in the Lonelygirl15 video series.
Transcript
Daniel: So you know that company I mentioned the other day? I found out where their main warehouse is located. I went to one of their satellite buildings yesterday, and it was all closed up. Hopefully this one's open. Sure looks shut down but... I'm gonna get in closer.
(Daniel walks through various fences and doors)
Daniel: I heard a car
(A car drives by, Daniel scrambles and runs from it, then sees a helicopter in the air)
(Daniel walks into an elevator, gets off into a dark room, turns on a flashlight)
Daniel: (Whispering) I hope I'm the only person in here.
(Daniel continues to look around, breathing heavily)
Daniel: Ever see that movie, Alien? I feel like Ripley.
(Cuts to hall)
Daniel: Maybe it's down there... this way...
(Looks around, breathing heavily, when a sudden large, creaking, door opening sound is made. You see that Daniel is opening a large garage-like door)
Daniel: There are all these boxes, that's the same symbol from the other box.
(All the boxes in room have same company logo as mentioned in Undisclosed Location)
(Creaking noises, music cuts back in)
(Daniel rummages through boxes of packing popcorn)
(Daniel picks up a medicine box with the word EPOGEN on it)
(Loud, eerie whirring)
Daniel: What the hell was that?! Oh my God...
(Frantic music plays as Daniel runs through a hallway, into an exit elevator)
(Daniel frantically presses elevator buttons)
(Cut to Daniel talking. He is no longer in a warehouse.)
Daniel: This is one of the boxes I found at the warehouse
(Camera pans to the medicine box he found)
Daniel: EP-O-GYN, or EI-PO-GEN... I dunno what this stuff is but... I'm guessing this is what they're injecting Bree with... which is weird, its not like she was sick. I'm gonna try and get in touch with Bree.
Notes
- Daniel found the lemniscate symbols again, on the boxes he found at the warehouse. The boxes contained styrofoam, and Epogen. This might be the stuff that was injected into Bree.
- Breaking and Entering is usually treated as a misdemeanor in the United States. Daniel learned many of his Breaking and Entering skills in the video Following The Helper in which he broke into Lucy's apartment. In this video, Daniel also steals something from the warehouse, which would be treated as burglary. Burglary is typically a felony in the United States. As in the past, Daniel is unconcerned about posting footage of criminal acts on YouTube.
- About Epogen: EPOGEN® is indicated for the treatment of anemia in patients with chronic renal failure on dialysis. Important Product Safety Information EPOGEN® is contraindicated in patients with uncontrolled hypertension. Erythropoietic therapies may increase the risk of seizures, thrombotic events, and other serious events. The target hemoglobin (Hb) should not exceed 12 g/dL. If the Hb increase exceeds 1.0 g/dL in any 2-week period, dose reductions are recommended. In a study with hemodialysis patients with clinically evident cardiac disease, where the target hematocrit (Hct) was 42% (Hb = 14 g/dL), an increased incidence of thrombotic events and mortality was seen. The reason for increased mortality observed in this study is unknown.Cases of pure red cell aplasia (PRCA) and of severe anemia, with or without other cytopenias associated with neutralizing antibodies to erythropoietin, have been reported in patients treated with EPOGEN®. A sudden loss of response to EPOGEN®, accompanied by severe anemia and low reticulocyte count, should be evaluated. If anti-erythropoietin antibody-associated anemia is suspected, withhold EPOGEN® and other erythropoietic proteins. EPOGEN® should be permanently discontinued in patients with antibody-mediated anemia. Patients should not be switched to other erythropoietic proteins.The most commonly reported side effects in clinical trials were hypertension, headache, arthralgias, and nausea.
